clinivation, Inc. - Announcements

Emerging leader in coronary and peripheral interventional markets selects clinivation Global xi to manage its medical products approvals and submissions.

Natick, MA, November 29, 2007 - clinivation, Inc. announced today that AngioScore, Inc. has selected clinivation Global^® xi Market Clearance Management solution.

"AngioScore is clearly an emerging leader in the development of angioplasty catheters used in coronary and peripheral artery disease, and we are pleased they have selected clinivation Global xi to help impact their market clearance operations," said Joseph Kozikowski, M.D., clinivation's Chief Executive Officer.

Clinivation Global xi software enables medical device companies to sell more products to more countries faster and easier than ever before. Clinivation Global xi is the first complete solution targeted at automating the business processes for market clearance operations worldwide.

AngioScore is a developer of novel angioplasty catheters for use in the treatment of coronary and peripheral artery disease. The company's flagship product, the AngioSculpt® Scoring Balloon Catheter, incorporates a unique system of nitinol-scoring elements with a traditional balloon catheter. The scoring elements create focal concentrations of dilating force, which minimize balloon slippage ("geographic miss") and assist in the luminal expansion of stenotic arteries.

AngioScore, Inc. is a privately held endovascular company, located in Fremont, California. For more information, please visit www.angioscore.com.

Clinivation's business is productivity- taking the time and labor out of making better medical products.

Since 1999, our productivity software and solutions have delivered superior value to market leaders in medical devices, pharmaceuticals, and diagnostics.

Visit clinivation online at www.clinivation.com.